MyMD Pharmaceuticals Enrolls First Person in Phase 2 Professional Test of MYMD-1 as a Therapy for Delaying Aging and also Expanding Healthy Lifespan

MyMD Pharmaceuticals, Inc. MYMD Stock News (” MyMD” or “the Business”), a clinical phase pharmaceutical business devoted to expanding healthy life expectancy, today revealed that the first client has actually been signed up in the Business’s Stage 2 professional trial of lead prospect MYMD-1, a dental immune regulator medicine, as a therapy for postponing aging and expanding healthy lifespan.

The primary endpoint for the Phase 2 double-blind, placebo-controlled scientific test is to achieve a reduction in the flowing degrees of (TNF-α), lump death element receptor I (TNFRI) as well as IL-6. TNF-α and also IL-6 are the healthy proteins in the body that trigger inflammation as well as help trigger the process of aging. The additional measures of the trial will be the safety and security, tolerability, and also pharmacokinetics in this population of individuals.

” In a Stage 1 scientific test of MYMD-1, we demonstrated the drug’s statistically considerable efficacy in lowering levels of TNF-α, a principal in triggering pathological aging, in the blood. The FDA has authorized TNF-α decrease as the primary endpoint for our Stage 2 research, which our team believe positions us well for an effective Stage 2 outcome,” claimed Chris Chapman, M.D., President, Director and also Chief Medical Officer of MyMD. “The initiation of individual registration in this research study breakthroughs our objective to reduce the aging procedure, stop loss of muscle tissue in aging, restriction frailty, and also prolong healthy and balanced life-span.”

MyMD has actually specified that there are no FDA-approved medications for treating aging disorders and also extending healthy and balanced lifespan people, a market anticipated to be at the very least $600 billion by 20251 according to a significant financial investment financial institution. TNF-α blockers are the most proposed medicines by income, a worldwide market of around $40 billion each year,2 and, according to Nature Aging journal,3 a slowdown in maturing that would certainly raise life expectancy by one year is worth $38 trillion and by one decade is worth $367 trillion.

In addition to aging, MYMD-1’s unique action in controling the immune system and treating persistent swelling is being developed for the treatment of autoimmune disease, including rheumatoid joint inflammation (RA), multiple sclerosis (MS), diabetic issues, and also inflammatory digestive tract disease.

” We intend to start writing procedures for a Phase 2 pilot research study of MYMD-1 for rheumatoid arthritis early this year,” Dr. Chapman noted. “The climbing frequency of rheumatoid arthritis and also various other autoimmune and also inflammatory conditions are driving need for TNF inhibitors like MYMD-1, and our team believe our by mouth provided medication with extremely reduced poisoning would be turbulent to the $60 billion market for RA if approved by the FDA for this indication.”

Rheumatoid joint inflammation influences roughly 40 million individuals worldwide.4.

Concerning MYMD-1.

Initially developed for autoimmune conditions, MYMD-1’s key function is to slow down the aging procedure, stop sarcopenia as well as frailty, as well as expand healthy and balanced life-span. Since it can go across the blood-brain obstacle as well as gain access to the central nervous system (CNS), MYMD-1 is likewise placed to be a possible treatment for brain-related conditions. Its mechanism of action and efficacy in conditions including several sclerosis (MS) as well as thyroiditis have actually been studied through cooperations with numerous scholastic organizations. MYMD-1 is likewise showing promise in pre-clinical studies as a possible treatment for post- COVID-19 issues and also as an anti-fibrotic and anti-proliferation restorative.

MYMD-1 has shown effectiveness in pre-clinical researches in controling the immune system by executing as a selective prevention of growth death factor-alpha (TNF-α), a driver of persistent swelling. Unlike various other treatments, MYMD-1 has actually been received these pre-clinical research studies to selectively obstruct TNF-α when it comes to be overactivated in autoimmune illness as well as cytokine storms, yet not obstruct it from doing its regular task of being a first responder to any routine sort of moderate infection. MYMD-1’s ease of oral dosing is another differentiator compared to currently offered TNF-α blockers, every one of which call for distribution by shot or mixture. No accepted TNF inhibitor has ever before been dosed orally. On top of that, the medicine is not immunosuppressive and also has actually not been shown to create the major adverse effects usual with conventional therapies that treat swelling.

Regarding MyMD Pharmaceuticals, Inc

. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a professional stage pharmaceutical company dedicated to expanding healthy and balanced life expectancy, is focused on creating two unique therapeutic systems that treat the reasons for disease as opposed to only addressing the signs. MYMD-1 is a drug platform based on a clinical phase little particle that regulates the immune system to manage TNF-α, which drives chronic swelling, and various other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, rise durability, and deal with autoimmune illness and COVID-19- associated depression. The Firm’s 2nd medication platform, Supera-CBD, is being created to treat chronic pain, addiction and also epilepsy. Supera-CBD is a novel synthetic by-product of cannabidiol (CBD) and also is being established to deal with and improve upon the rapidly expanding CBD market, that includes both FDA authorized medications and also CBD items not currently managed as drugs. For more information, go to

You may also like